Psychiatric Disorder Ion Channel Portfolio

Antipsychotic and antianxiety drugs targeting ion channels are believed to modulate synaptic transmission in specific brain regions, including the limbic system in schizophrenia and the limbic and brainstem reticular activating systems in anxiety. Voltage-gated calcium channels such as Cav1.3/β3/α2δ contribute to neurotransmitter release and synaptic plasticity. GABA receptors including α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2 and α5β3γ2 mediate GABAergic transmission that is central to anxiety modulation. Nicotinic acetylcholine receptors including α4/β2, α7, α3β4α5 and α6/3β2β3 are potential targets for cognitive enhancement in schizophrenia. NMDA receptor complexes including NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D regulate glutamatergic neurotransmission and are relevant to schizophrenia and related disorders. Voltage-gated potassium channels such as KCNQ2/3 and KCNQ3/5 regulate neuronal excitability, while calcium-activated potassium channels including SK1, SK2 and SK3 contribute to neuronal excitability and synaptic plasticity.

Psychiatric Disorder Ion Channel Portfolio

Our Psychiatric Disorder Ion Channel Portfolio is designed to identify and profile ion channels and neurotransmitter receptor channels that are critical to the pathophysiology of psychiatric disorders, particularly anxiety and schizophrenia. The panel supports the development of therapeutics intended to modulate synaptic transmission and provides a focused framework for evaluating target specificity and potential off-target effects.